Xcytrin
information and resources from the National Cancer Institute
Xcytrin
(Other name for: motexafin gadolinium)
Xcytrin
(Other name for: motexafin gadolinium)
|
|
|
|
news articles
Pharmacyclics' Stock Crushed After Failed Phase III Of Xcytrin Dec 19, 2005
BioWorld Online (subscription), A missed primary endpoint in a pivotal study of its lung cancer brain metastases drug, Xcytrin, sent Pharmacyclics Inc.'s stock plunging more than 64 percent ...
Pharmacyclics Announces Presentation and Published Abstracts on ... Dec 6, 2005
PR Newswire (press release), ...(Nasdaq: PCYC) announced today a presentation and multiple published abstracts regarding Xcytrin(R) (motexafin gadolinium) Injection. ...
Stocks in Motion: Pharmacyclics Dec 19, 2005
TheStreet.com The company's shares tumbled 63% after a late-stage trial of its lung cancer drug, Xcytrin, failed to show statistical significance. ...
Pharmacyclics Announces Presentation and Publication of ... Dec 12, 2005
PharmaLive.com (press release), ...today announced the presentation of preliminary results of a Phase 1 clinical trial, which suggest that Xcytrin(R) (motexafin gadolinium) Injection, when given ...
(PRN) - KPMG International Releases 2005 Annual Review ... [+] Dec 18, 2005
Bolsamania.com, ...(PRN) - Pharmacyclics Announces Conference Call on Monday December 19 at 8:30 am Eastern Time to Discuss Xcytrin Phase 3 Results ... [+. ...
Pharmacyclics Announces Motexafin Gadolinium Improved Survival in ... Dec 8, 2005
PR Newswire (press release), ...(Nasdaq: PCYC) today announced the presentation of preclinical data showing that motexafin gadolinium (MGd), the active chemical agent in Xcytrin(R) Injection ...
Market Highlights Dec 19, 2005
Winston-Salem Journal, Pharmacyclics Inc., down $5.90 to close at $3.30. The company said its experimental lung-cancer drug Xcytrin failed a recent late-stage study.
Pharmacyclics Announces Motexafin Gadolinium Improved Survival in ... Dec 8, 2005
PharmaLive.com (press release), ...today announced the presentation of preclinical data showing that motexafin gadolinium (MGd), the active chemical agent in Xcytrin(R) Injection, the company's ...
(PRN) - Tibotec Presents Phase 2b Data on 2 Investigational HIV ... Dec 19, 2005
Bolsamania.com, Facilities ... [+. PRN) - Pharmacyclics Announces Results from Phase 3 Smart Trial of Xcytrin(R) for Lung Cancer Brain Metastases ... [+. ...
(PRN) - MTI Instruments Announces Retirement of Vice President and ... Dec 6, 2005
Bolsamania.com, ...(PRN) - Pharmacyclics Announces Presentation and Published Abstracts on Xcytrin at the American Society of Hematology (ASH) 47th Annual Meeting and Exposition ...
(PRN) - Misys Banking Systems Brings Automation to the Precious ... Dec 12, 2005
Bolsamania.com, ...[+]. (PRN) - Pharmacyclics Announces Presentation and Publication of Preliminary Results Evaluating Xcytrin for the Treatment of Refractory B-cell Lymphomas ... ...
Pharmacyclics' Stock Crushed After Failed Phase III Of Xcytrin Dec 19, 2005
BioWorld Online (subscription), A missed primary endpoint in a pivotal study of its lung cancer brain metastases drug, Xcytrin, sent Pharmacyclics Inc.'s stock plunging more than 64 percent ...
Pharmacyclics Announces Presentation and Published Abstracts on ... Dec 6, 2005
PR Newswire (press release), ...(Nasdaq: PCYC) announced today a presentation and multiple published abstracts regarding Xcytrin(R) (motexafin gadolinium) Injection. ...
Stocks in Motion: Pharmacyclics Dec 19, 2005
TheStreet.com The company's shares tumbled 63% after a late-stage trial of its lung cancer drug, Xcytrin, failed to show statistical significance. ...
Pharmacyclics Announces Presentation and Publication of ... Dec 12, 2005
PharmaLive.com (press release), ...today announced the presentation of preliminary results of a Phase 1 clinical trial, which suggest that Xcytrin(R) (motexafin gadolinium) Injection, when given ...
(PRN) - KPMG International Releases 2005 Annual Review ... [+] Dec 18, 2005
Bolsamania.com, ...(PRN) - Pharmacyclics Announces Conference Call on Monday December 19 at 8:30 am Eastern Time to Discuss Xcytrin Phase 3 Results ... [+. ...
Pharmacyclics Announces Motexafin Gadolinium Improved Survival in ... Dec 8, 2005
PR Newswire (press release), ...(Nasdaq: PCYC) today announced the presentation of preclinical data showing that motexafin gadolinium (MGd), the active chemical agent in Xcytrin(R) Injection ...
Market Highlights Dec 19, 2005
Winston-Salem Journal, Pharmacyclics Inc., down $5.90 to close at $3.30. The company said its experimental lung-cancer drug Xcytrin failed a recent late-stage study.
Pharmacyclics Announces Motexafin Gadolinium Improved Survival in ... Dec 8, 2005
PharmaLive.com (press release), ...today announced the presentation of preclinical data showing that motexafin gadolinium (MGd), the active chemical agent in Xcytrin(R) Injection, the company's ...
(PRN) - Tibotec Presents Phase 2b Data on 2 Investigational HIV ... Dec 19, 2005
Bolsamania.com, Facilities ... [+. PRN) - Pharmacyclics Announces Results from Phase 3 Smart Trial of Xcytrin(R) for Lung Cancer Brain Metastases ... [+. ...
(PRN) - MTI Instruments Announces Retirement of Vice President and ... Dec 6, 2005
Bolsamania.com, ...(PRN) - Pharmacyclics Announces Presentation and Published Abstracts on Xcytrin at the American Society of Hematology (ASH) 47th Annual Meeting and Exposition ...
(PRN) - Misys Banking Systems Brings Automation to the Precious ... Dec 12, 2005
Bolsamania.com, ...[+]. (PRN) - Pharmacyclics Announces Presentation and Publication of Preliminary Results Evaluating Xcytrin for the Treatment of Refractory B-cell Lymphomas ... ...
|
|
